NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a research report issued on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock.

Several other equities research analysts have also issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Zacks Research downgraded NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $36.75.

NRx Pharmaceuticals Price Performance

NRXP traded up $0.05 during midday trading on Wednesday, hitting $1.85. 179,376 shares of the company’s stock traded hands, compared to its average volume of 1,304,563. The company has a market cap of $54.61 million, a PE ratio of -0.79 and a beta of 1.91. The stock’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $2.56. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the 3rd quarter valued at $39,000. Sjbenen Advisory LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC raised its position in NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the last quarter. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter worth $107,000. Finally, Two Sigma Investments LP grew its holdings in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.